Insulin market in China
Release date:2019-11-25

Insulin is a protein hormone secreted by islet cells in the pancreas.Is the only hormone in the body that lowers blood sugar.At the same time, insulin can promote the synthesis of glycogen, fat and protein.After insulin is involved in regulating glucose metabolism and controlling blood glucose balance, the secretion of insulin will increase the blood glucose concentration in the body, leading to diabetes.
With the improvement of people's living standards, the incidence of diabetes is increasing rapidly all over the world.The incidence of diabetes in China also showed a rapid increase.According to the international diabetes federation (IDF), the number of people with diabetes is increasing rapidly around the world, reaching 382 million in 2013 and 592 million by 2035.China has 92.4 million diabetes patients, ranking first in the world.With the improvement of national medical insurance policies, the acceleration of aging society, the promotion of expert education, the change of insulin use concept, the strengthening of self-care and the rapid development of recombinant human insulin localization, the rapid growth of the domestic insulin market has been accelerated.
The rapid development of the market has brought unprecedented opportunities for domestic insulin enterprises, and the major species of recombinant insulin including insulin glargine, insulin mendonde, recombinant human insulin and insulin lyserin have made important contributions.In the domestic insulin market is still the world of foreign brands, but the domestic insulin industry is beginning to take shape, and the opening of the market is just around the corner.